

## Going Strong In Hepatitis Drug Profile

04 July 2015 | Analysis | By BioSpectrum Bureau

### Going Strong In Hepatitis Drug Profile



#### Singapore:

##### **SINO BIOPHARMACEUTICAL, China**

**Chairman:** Mr Ping Tse

**Revenue:** \$1534.8 mn

**Business:** Research, development, manufacturing and marketing of Chinese medicines and chemical medicines

Sino Biopharmaceutical recorded a turnover of \$1534.8 million clocking an increase of approx. 25 percent from the previous year. The sales of hepatitis medicines amounted to around \$745.4 million, representing approx. 46.7 percent of the company's turnover.

Cardio-cerebral medicines registered sale of \$391.5 million, marking approx. 19.8 percent of the turnover of the group and oncology medicines amounted to around \$1451.6 million, an increase of 38.8 percent from the previous year.

In 2014, Sino Biopharmaceutical obtained eight production approvals, 11 clinical applications, 12 product new applications, six production applications after clinical completion, 57 new clinical applications and 64 filed productions. Moreover, a total of 238 pharmaceutical products completed clinical research, or were under clinical trial or applying for production approval. Out of these, 36 were for cardio-cerebral medicines, 13 for hepatitis medicines, 96 for oncology medicines, 16 for respiratory system medicines, 17 for diabetic medicines and 60 for other medicines.

In 2014, Sino Biopharmaceutical launched new products in the hepatitis and cardio-cerebral segment including Maleicacid Entecavir capsules and Rosuvastatin calcium tablets that are projected to be next growth driver of the company. It further expanded its oncology category by adding new products such as Imatinib Mesylate capsules, Dasatinib tablets and Decitabine that exhibited impressive sales in their debut.

